Temporal linear mode complexity as a surrogate measure of the effect of remifentanil on the central nervous system in healthy volunteers
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Remifentanil, an intravenous ultra short‐acting opioid, depresses central nervous system activity with an increase in the delta band power, and causes beta activation after discontinuation, resulting in a rebound of the processed electroencephalographic par...
Saved in:
| Published in | British journal of clinical pharmacology Vol. 71; no. 6; pp. 871 - 885 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Oxford, UK
Blackwell Publishing Ltd
01.06.2011
Blackwell Blackwell Science Inc |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Remifentanil, an intravenous ultra short‐acting opioid, depresses central nervous system activity with an increase in the delta band power, and causes beta activation after discontinuation, resulting in a rebound of the processed electroencephalographic parameters, including 95% spectral edge frequency, the canonical univariate parameter and electroencephalographic approximate entropy.
• A sigmoid Emax model, in which the highest predicted values of processed electroencephalographic parameters are restricted to the baseline value, cannot describe a rebound of these parameters.
• Electroencephalographic approximate entropy correlated well with the remifentanil blood concentration and demonstrated high baseline stability.
WHAT THIS STUDY ADDS
• A combined effect and tolerance model effectively characterized the time course of the remifentanil effect on the central nervous system, including the rebound which occurred during recovery from the remifentanil effect.
• Temporal linear mode complexity was comparable with approximate entropy as a univariate electroencephalographic descriptor of the effect of remifentanil on the central nervous system.
AIMS Previously, electroencephalographic approximate entropy (ApEn) effectively described both depression of central nervous system (CNS) activity and rebound during and after remifentanil infusion. ApEn is heavily dependent on the record length. Linear mode complexity, which is algorithmatically independent of the record length, was investigated to characterize the effect of remifentanil on the CNS using the combined effect and tolerance, feedback and sigmoid Emax models.
METHODS The remifentanil blood concentrations and electroencephalographic data obtained in our previous study were used. With the recording of the electroencephalogram, remifentanil was infused at a rate of 1, 2, 3, 4, 5, 6, 7 or 8 µg kg−1 min−1 for 15–20 min. The areas below (AUCeffect) or above (AACrebound) the effect vs. time curve of temporal linear mode complexity (TLMC) and ApEn were calculated to quantitate the decrease of the CNS activity and rebound. The coefficients of variation (CV) of median baseline (E0), maximal (Emax), and individual median E0 minus Emax values of TLMC were compared with those of ApEn. The concentration–TLMC relationship was characterized by population analysis using non‐linear mixed effects modelling.
RESULTS Median AUCeffect and AACrebound were 1016 and 5.3 (TLMC), 787 and 4.5 (ApEn). The CVs of individual median E0 minus Emax were 35.6, 32.5% (TLMC, ApEn). The combined effect and tolerance model demonstrated the lowest Akaike information criteria value and the highest positive predictive value of rebound in tolerance.
CONCLUSIONS The combined effect and tolerance model effectively characterized the time course of TLMC as a surrogate measure of the effect of remifentanil on the CNS. |
|---|---|
| AbstractList | • Remifentanil, an intravenous ultra short-acting opioid, depresses central nervous system activity with an increase in the delta band power, and causes beta activation after discontinuation, resulting in a rebound of the processed electroencephalographic parameters, including 95% spectral edge frequency, the canonical univariate parameter and electroencephalographic approximate entropy. • A sigmoid Emax model, in which the highest predicted values of processed electroencephalographic parameters are restricted to the baseline value, cannot describe a rebound of these parameters. • Electroencephalographic approximate entropy correlated well with the remifentanil blood concentration and demonstrated high baseline stability.WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Remifentanil, an intravenous ultra short-acting opioid, depresses central nervous system activity with an increase in the delta band power, and causes beta activation after discontinuation, resulting in a rebound of the processed electroencephalographic parameters, including 95% spectral edge frequency, the canonical univariate parameter and electroencephalographic approximate entropy. • A sigmoid Emax model, in which the highest predicted values of processed electroencephalographic parameters are restricted to the baseline value, cannot describe a rebound of these parameters. • Electroencephalographic approximate entropy correlated well with the remifentanil blood concentration and demonstrated high baseline stability.• A combined effect and tolerance model effectively characterized the time course of the remifentanil effect on the central nervous system, including the rebound which occurred during recovery from the remifentanil effect. • Temporal linear mode complexity was comparable with approximate entropy as a univariate electroencephalographic descriptor of the effect of remifentanil on the central nervous system. AIMS Previously, electroencephalographic approximate entropy (ApEn) effectively described both depression of central nervous system (CNS) activity and rebound during and after remifentanil infusion. ApEn is heavily dependent on the record length. Linear mode complexity, which is algorithmatically independent of the record length, was investigated to characterize the effect of remifentanil on the CNS using the combined effect and tolerance, feedback and sigmoid E(max) models. METHODS The remifentanil blood concentrations and electroencephalographic data obtained in our previous study were used. With the recording of the electroencephalogram, remifentanil was infused at a rate of 1, 2, 3, 4, 5, 6, 7 or 8 µg kg(-1) min(-1) for 15-20 min. The areas below (AUC(effect) ) or above (AAC(rebound) ) the effect vs. time curve of temporal linear mode complexity (TLMC) and ApEn were calculated to quantitate the decrease of the CNS activity and rebound. The coefficients of variation (CV) of median baseline (E(0)), maximal (E(max)), and individual median E(0) minus E(max) values of TLMC were compared with those of ApEn. The concentration-TLMC relationship was characterized by population analysis using non-linear mixed effects modelling.WHAT THIS STUDY ADDS• A combined effect and tolerance model effectively characterized the time course of the remifentanil effect on the central nervous system, including the rebound which occurred during recovery from the remifentanil effect. • Temporal linear mode complexity was comparable with approximate entropy as a univariate electroencephalographic descriptor of the effect of remifentanil on the central nervous system. AIMS Previously, electroencephalographic approximate entropy (ApEn) effectively described both depression of central nervous system (CNS) activity and rebound during and after remifentanil infusion. ApEn is heavily dependent on the record length. Linear mode complexity, which is algorithmatically independent of the record length, was investigated to characterize the effect of remifentanil on the CNS using the combined effect and tolerance, feedback and sigmoid E(max) models. METHODS The remifentanil blood concentrations and electroencephalographic data obtained in our previous study were used. With the recording of the electroencephalogram, remifentanil was infused at a rate of 1, 2, 3, 4, 5, 6, 7 or 8 µg kg(-1) min(-1) for 15-20 min. The areas below (AUC(effect) ) or above (AAC(rebound) ) the effect vs. time curve of temporal linear mode complexity (TLMC) and ApEn were calculated to quantitate the decrease of the CNS activity and rebound. The coefficients of variation (CV) of median baseline (E(0)), maximal (E(max)), and individual median E(0) minus E(max) values of TLMC were compared with those of ApEn. The concentration-TLMC relationship was characterized by population analysis using non-linear mixed effects modelling.Median AUC(effect) and AAC(rebound) were 1016 and 5.3 (TLMC), 787 and 4.5 (ApEn). The CVs of individual median E(0) minus E(max) were 35.6, 32.5% (TLMC, ApEn). The combined effect and tolerance model demonstrated the lowest Akaike information criteria value and the highest positive predictive value of rebound in tolerance.RESULTSMedian AUC(effect) and AAC(rebound) were 1016 and 5.3 (TLMC), 787 and 4.5 (ApEn). The CVs of individual median E(0) minus E(max) were 35.6, 32.5% (TLMC, ApEn). The combined effect and tolerance model demonstrated the lowest Akaike information criteria value and the highest positive predictive value of rebound in tolerance.The combined effect and tolerance model effectively characterized the time course of TLMC as a surrogate measure of the effect of remifentanil on the CNS.CONCLUSIONSThe combined effect and tolerance model effectively characterized the time course of TLMC as a surrogate measure of the effect of remifentanil on the CNS. times Remifentanil, an intravenous ultra short-acting opioid, depresses central nervous system activity with an increase in the delta band power, and causes beta activation after discontinuation, resulting in a rebound of the processed electroencephalographic parameters, including 95% spectral edge frequency, the canonical univariate parameter and electroencephalographic approximate entropy. times A sigmoid Emax model, in which the highest predicted values of processed electroencephalographic parameters are restricted to the baseline value, cannot describe a rebound of these parameters. times Electroencephalographic approximate entropy correlated well with the remifentanil blood concentration and demonstrated high baseline stability. WHAT THIS STUDY ADDS times A combined effect and tolerance model effectively characterized the time course of the remifentanil effect on the central nervous system, including the rebound which occurred during recovery from the remifentanil effect. times Temporal linear mode complexity was comparable with approximate entropy as a univariate electroencephalographic descriptor of the effect of remifentanil on the central nervous system. AIMS Previously, electroencephalographic approximate entropy (ApEn) effectively described both depression of central nervous system (CNS) activity and rebound during and after remifentanil infusion. ApEn is heavily dependent on the record length. Linear mode complexity, which is algorithmatically independent of the record length, was investigated to characterize the effect of remifentanil on the CNS using the combined effect and tolerance, feedback and sigmoid Emax models. METHODS The remifentanil blood concentrations and electroencephalographic data obtained in our previous study were used. With the recording of the electroencephalogram, remifentanil was infused at a rate of 1, 2, 3, 4, 5, 6, 7 or 8 mu gkg-1min-1 for 15-20min. The areas below (AUCeffect) or above (AACrebound) the effect vs. time curve of temporal linear mode complexity (TLMC) and ApEn were calculated to quantitate the decrease of the CNS activity and rebound. The coefficients of variation (CV) of median baseline (E0), maximal (Emax), and individual median E0 minus Emax values of TLMC were compared with those of ApEn. The concentration-TLMC relationship was characterized by population analysis using non-linear mixed effects modelling. RESULTS Median AUCeffect and AACrebound were 1016 and 5.3 (TLMC), 787 and 4.5 (ApEn). The CVs of individual median E0 minus Emax were 35.6, 32.5% (TLMC, ApEn). The combined effect and tolerance model demonstrated the lowest Akaike information criteria value and the highest positive predictive value of rebound in tolerance. CONCLUSIONS The combined effect and tolerance model effectively characterized the time course of TLMC as a surrogate measure of the effect of remifentanil on the CNS.Original Abstract: WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Remifentanil, an intravenous ultra short‐acting opioid, depresses central nervous system activity with an increase in the delta band power, and causes beta activation after discontinuation, resulting in a rebound of the processed electroencephalographic parameters, including 95% spectral edge frequency, the canonical univariate parameter and electroencephalographic approximate entropy. • A sigmoid Emax model, in which the highest predicted values of processed electroencephalographic parameters are restricted to the baseline value, cannot describe a rebound of these parameters. • Electroencephalographic approximate entropy correlated well with the remifentanil blood concentration and demonstrated high baseline stability. WHAT THIS STUDY ADDS • A combined effect and tolerance model effectively characterized the time course of the remifentanil effect on the central nervous system, including the rebound which occurred during recovery from the remifentanil effect. • Temporal linear mode complexity was comparable with approximate entropy as a univariate electroencephalographic descriptor of the effect of remifentanil on the central nervous system. AIMS Previously, electroencephalographic approximate entropy (ApEn) effectively described both depression of central nervous system (CNS) activity and rebound during and after remifentanil infusion. ApEn is heavily dependent on the record length. Linear mode complexity, which is algorithmatically independent of the record length, was investigated to characterize the effect of remifentanil on the CNS using the combined effect and tolerance, feedback and sigmoid E max models. METHODS The remifentanil blood concentrations and electroencephalographic data obtained in our previous study were used. With the recording of the electroencephalogram, remifentanil was infused at a rate of 1, 2, 3, 4, 5, 6, 7 or 8 µg kg −1 min −1 for 15–20 min. The areas below (AUC effect ) or above (AAC rebound ) the effect vs. time curve of temporal linear mode complexity (TLMC) and ApEn were calculated to quantitate the decrease of the CNS activity and rebound. The coefficients of variation (CV) of median baseline (E 0 ), maximal (E max ), and individual median E 0 minus E max values of TLMC were compared with those of ApEn. The concentration–TLMC relationship was characterized by population analysis using non‐linear mixed effects modelling. RESULTS Median AUC effect and AAC rebound were 1016 and 5.3 (TLMC), 787 and 4.5 (ApEn). The CVs of individual median E 0 minus E max were 35.6, 32.5% (TLMC, ApEn). The combined effect and tolerance model demonstrated the lowest Akaike information criteria value and the highest positive predictive value of rebound in tolerance. CONCLUSIONS The combined effect and tolerance model effectively characterized the time course of TLMC as a surrogate measure of the effect of remifentanil on the CNS. • Remifentanil, an intravenous ultra short-acting opioid, depresses central nervous system activity with an increase in the delta band power, and causes beta activation after discontinuation, resulting in a rebound of the processed electroencephalographic parameters, including 95% spectral edge frequency, the canonical univariate parameter and electroencephalographic approximate entropy. • A sigmoid Emax model, in which the highest predicted values of processed electroencephalographic parameters are restricted to the baseline value, cannot describe a rebound of these parameters. • Electroencephalographic approximate entropy correlated well with the remifentanil blood concentration and demonstrated high baseline stability. • A combined effect and tolerance model effectively characterized the time course of the remifentanil effect on the central nervous system, including the rebound which occurred during recovery from the remifentanil effect. • Temporal linear mode complexity was comparable with approximate entropy as a univariate electroencephalographic descriptor of the effect of remifentanil on the central nervous system. AIMS Previously, electroencephalographic approximate entropy (ApEn) effectively described both depression of central nervous system (CNS) activity and rebound during and after remifentanil infusion. ApEn is heavily dependent on the record length. Linear mode complexity, which is algorithmatically independent of the record length, was investigated to characterize the effect of remifentanil on the CNS using the combined effect and tolerance, feedback and sigmoid E(max) models. METHODS The remifentanil blood concentrations and electroencephalographic data obtained in our previous study were used. With the recording of the electroencephalogram, remifentanil was infused at a rate of 1, 2, 3, 4, 5, 6, 7 or 8 µg kg(-1) min(-1) for 15-20 min. The areas below (AUC(effect) ) or above (AAC(rebound) ) the effect vs. time curve of temporal linear mode complexity (TLMC) and ApEn were calculated to quantitate the decrease of the CNS activity and rebound. The coefficients of variation (CV) of median baseline (E(0)), maximal (E(max)), and individual median E(0) minus E(max) values of TLMC were compared with those of ApEn. The concentration-TLMC relationship was characterized by population analysis using non-linear mixed effects modelling. Median AUC(effect) and AAC(rebound) were 1016 and 5.3 (TLMC), 787 and 4.5 (ApEn). The CVs of individual median E(0) minus E(max) were 35.6, 32.5% (TLMC, ApEn). The combined effect and tolerance model demonstrated the lowest Akaike information criteria value and the highest positive predictive value of rebound in tolerance. The combined effect and tolerance model effectively characterized the time course of TLMC as a surrogate measure of the effect of remifentanil on the CNS. WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Remifentanil, an intravenous ultra short‐acting opioid, depresses central nervous system activity with an increase in the delta band power, and causes beta activation after discontinuation, resulting in a rebound of the processed electroencephalographic parameters, including 95% spectral edge frequency, the canonical univariate parameter and electroencephalographic approximate entropy. • A sigmoid Emax model, in which the highest predicted values of processed electroencephalographic parameters are restricted to the baseline value, cannot describe a rebound of these parameters. • Electroencephalographic approximate entropy correlated well with the remifentanil blood concentration and demonstrated high baseline stability. WHAT THIS STUDY ADDS • A combined effect and tolerance model effectively characterized the time course of the remifentanil effect on the central nervous system, including the rebound which occurred during recovery from the remifentanil effect. • Temporal linear mode complexity was comparable with approximate entropy as a univariate electroencephalographic descriptor of the effect of remifentanil on the central nervous system. AIMS Previously, electroencephalographic approximate entropy (ApEn) effectively described both depression of central nervous system (CNS) activity and rebound during and after remifentanil infusion. ApEn is heavily dependent on the record length. Linear mode complexity, which is algorithmatically independent of the record length, was investigated to characterize the effect of remifentanil on the CNS using the combined effect and tolerance, feedback and sigmoid Emax models. METHODS The remifentanil blood concentrations and electroencephalographic data obtained in our previous study were used. With the recording of the electroencephalogram, remifentanil was infused at a rate of 1, 2, 3, 4, 5, 6, 7 or 8 µg kg−1 min−1 for 15–20 min. The areas below (AUCeffect) or above (AACrebound) the effect vs. time curve of temporal linear mode complexity (TLMC) and ApEn were calculated to quantitate the decrease of the CNS activity and rebound. The coefficients of variation (CV) of median baseline (E0), maximal (Emax), and individual median E0 minus Emax values of TLMC were compared with those of ApEn. The concentration–TLMC relationship was characterized by population analysis using non‐linear mixed effects modelling. RESULTS Median AUCeffect and AACrebound were 1016 and 5.3 (TLMC), 787 and 4.5 (ApEn). The CVs of individual median E0 minus Emax were 35.6, 32.5% (TLMC, ApEn). The combined effect and tolerance model demonstrated the lowest Akaike information criteria value and the highest positive predictive value of rebound in tolerance. CONCLUSIONS The combined effect and tolerance model effectively characterized the time course of TLMC as a surrogate measure of the effect of remifentanil on the CNS. |
| Author | Lee, Soo‐Han Choi, Byung‐Moon Noh, Moon‐Ho Noh, Gyu‐Jeong Jeong, Yong‐Bo Shin, Da‐Huin Kim, Young‐Hac Lee, Eun‐Kyung |
| Author_xml | – sequence: 1 givenname: Byung‐Moon surname: Choi fullname: Choi, Byung‐Moon – sequence: 2 givenname: Da‐Huin surname: Shin fullname: Shin, Da‐Huin – sequence: 3 givenname: Moon‐Ho surname: Noh fullname: Noh, Moon‐Ho – sequence: 4 givenname: Young‐Hac surname: Kim fullname: Kim, Young‐Hac – sequence: 5 givenname: Yong‐Bo surname: Jeong fullname: Jeong, Yong‐Bo – sequence: 6 givenname: Soo‐Han surname: Lee fullname: Lee, Soo‐Han – sequence: 7 givenname: Eun‐Kyung surname: Lee fullname: Lee, Eun‐Kyung – sequence: 8 givenname: Gyu‐Jeong surname: Noh fullname: Noh, Gyu‐Jeong |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24163169$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21223358$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNUstuEzEUtVARTQO_gLxBsEnwY-yZWYAEES-pEizK2nI8140jjx3sSUj-gM_G04QUNqhe2L46x8f3ca7QRYgBEMKUzGlZr9dzyqWYMcrEnBFK54S3pJrvH6HJGbhAE8KJnAkm6CW6ynlNCOVUiifosuCMc9FM0K8b6DcxaY-9C6AT7mMH2MR-42HvhgPWGWuctynFWz0A7kGXAHC0eFgBBmvBDGOUoHcWwqCD8ziGO9SUeJQOkHZxm3E-5AF67AJegfbD6oB30W_DAJDyU_TYap_h2emcou8fP9wsPs-uv376snh3PTOCy2pWNVZ3NdRVx4gwHbWcE1rXVWtltRRkSbkWraDSNoxVjFK5ZEbWNaus6JYta_kUvT3qbrbLHrpTimqTXK_TQUXt1L9IcCt1G3eKk7bldVUEXp4EUvyxhTyo3mUD3usApUjVSCk4r0qvp-jVf5mUsIY0RHJSqM__zuqczp9BFcKLE0Fno71NOhiX73kVlWW2Y3nNkWdSzDmBPVMoUaN31FqNFhmVy1a8o-68o_b3nTk_NW7Qg4tjH5x_iMCbo8BP5-Hw4I_V-8W38cZ_A94G3sM |
| CODEN | BCPHBM |
| CitedBy_id | crossref_primary_10_1111_1440_1681_12677 crossref_primary_10_1016_j_psychres_2017_06_041 crossref_primary_10_1016_j_xphs_2018_08_017 crossref_primary_10_1155_2017_3521261 crossref_primary_10_1155_2016_2304356 crossref_primary_10_4097_kjae_2013_65_5_385 |
| Cites_doi | 10.1159/000048685 10.1093/bioinformatics/3.4.345 10.1097/00000542-199601000-00005 10.1063/1.166092 10.1002/0470087978 10.1378/chest.122.5.1627 10.1016/S0022-3565(25)24269-0 10.1016/j.ejps.2007.06.001 10.1097/00000542-200303000-00008 10.1007/978-3-0348-8501-0 10.1097/00000542-200605000-00006 10.1016/S0022-3565(24)36639-X 10.1016/S0022-3565(25)39480-2 10.1097/00000542-199304000-00020 10.1038/sj.clpt.6100241 10.1038/clpt.1989.195 10.1016/j.eplepsyres.2007.08.002 10.1016/S0022-3565(25)24264-1 10.1016/S0022-3565(24)34948-1 10.1016/0167-2789(92)90103-T 10.2460/javma.1986.188.12.1426 10.1016/S0022-3565(25)38315-1 10.1016/S0022-3565(25)31325-X 10.1016/0013-4694(85)90036-7 10.1103/PhysRevLett.50.346 10.1146/annurev.bioeng.5.040202.121601 10.1007/BFb0091924 10.5194/hessd-2-365-2005 10.1080/01621459.1968.10480932 10.1111/j.1365-2125.2007.02845.x 10.1016/S0169-2607(98)00098-4 10.1097/00005344-198000021-00008 10.1152/ajpheart.2000.278.6.H2039 10.1097/00000542-199510000-00014 10.1109/10.995684 |
| ContentType | Journal Article |
| Copyright | 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society 2015 INIST-CNRS 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society. Copyright © 2011 The British Pharmacological Society 2011 |
| Copyright_xml | – notice: 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society – notice: 2015 INIST-CNRS – notice: 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society. – notice: Copyright © 2011 The British Pharmacological Society 2011 |
| DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TK 7X8 5PM |
| DOI | 10.1111/j.1365-2125.2011.03904.x |
| DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Neurosciences Abstracts CrossRef MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1365-2125 |
| EndPage | 885 |
| ExternalDocumentID | PMC3099374 21223358 24163169 10_1111_j_1365_2125_2011_03904_x BCP3904 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABOCM ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFEBI AFFPM AFGKR AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AIACR AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HYE HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAHHS AAYXX ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE CITATION IQODW 24P AEUQT AFPWT CGR CUY CVF ECM EIF ESX FIJ IPNFZ NPM RPM WRC 7TK 7X8 5PM |
| ID | FETCH-LOGICAL-c5364-48fad7e74d205cd1f33017749f64b50b13a59516f82242116b2c67724f5db9293 |
| IEDL.DBID | DR2 |
| ISSN | 0306-5251 1365-2125 |
| IngestDate | Thu Aug 21 18:31:00 EDT 2025 Fri Jul 11 09:49:32 EDT 2025 Fri Jul 11 15:04:16 EDT 2025 Wed Feb 19 01:48:22 EST 2025 Mon Jul 21 09:13:10 EDT 2025 Tue Jul 01 05:28:32 EDT 2025 Thu Apr 24 23:09:21 EDT 2025 Wed Aug 20 07:27:39 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | Human Agonist Pharmacodynamics Healthy subject Toxicity μ Opioid receptor Central nervous system Tolerance Opiates feedback model Narcotic analgesic Biological activity Remifentanil Complexity temporal linear mode complexity Feedback Models model Phenylpiperidine derivatives Sedative sigmoid E combined effect and tolerance model |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 2011 The Authors. British Journal of Clinical Pharmacology © 2011 The British Pharmacological Society. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5364-48fad7e74d205cd1f33017749f64b50b13a59516f82242116b2c67724f5db9293 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.2011.03904.x |
| PMID | 21223358 |
| PQID | 1028080630 |
| PQPubID | 23462 |
| PageCount | 15 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3099374 proquest_miscellaneous_866533401 proquest_miscellaneous_1028080630 pubmed_primary_21223358 pascalfrancis_primary_24163169 crossref_primary_10_1111_j_1365_2125_2011_03904_x crossref_citationtrail_10_1111_j_1365_2125_2011_03904_x wiley_primary_10_1111_j_1365_2125_2011_03904_x_BCP3904 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | June 2011 |
| PublicationDateYYYYMMDD | 2011-06-01 |
| PublicationDate_xml | – month: 06 year: 2011 text: June 2011 |
| PublicationDecade | 2010 |
| PublicationPlace | Oxford, UK |
| PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
| PublicationTitle | British journal of clinical pharmacology |
| PublicationTitleAlternate | Br J Clin Pharmacol |
| PublicationYear | 2011 |
| Publisher | Blackwell Publishing Ltd Blackwell Blackwell Science Inc |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell – name: Blackwell Science Inc |
| References | 1987; 3 2000; 278 1999; 290 1988; 244 2007 2004; 6 2006 1994 1992; 58 1983; 50 1985; 60 1992 1993; 267 2007; 32 2007; 77 1989; 46 2003; 98 1995; 5 1993; 266 1968; 63 2002; 49 1995; 83 1993; 78 1997; 281 1986; 188 2002; 45 1980; 2 1999; 59 2002; 122 1996; 84 2007; 82 1981; 898 2005; 2 2007; 64 2006; 104 1978; 206 e_1_2_7_5_2 e_1_2_7_4_2 e_1_2_7_3_2 e_1_2_7_9_2 e_1_2_7_8_2 e_1_2_7_6_2 e_1_2_7_19_2 Gardmark M (e_1_2_7_7_2) 1993; 267 e_1_2_7_18_2 e_1_2_7_11_2 e_1_2_7_10_2 Porchet HC (e_1_2_7_12_2) 1988; 244 Beal S (e_1_2_7_17_2) 1992 Brynne L (e_1_2_7_27_2) 1999; 290 e_1_2_7_28_2 Ette EI (e_1_2_7_15_2) 2007 e_1_2_7_24_2 e_1_2_7_30_2 Ouellet DM (e_1_2_7_14_2) 1997; 281 e_1_2_7_23_2 e_1_2_7_31_2 e_1_2_7_22_2 e_1_2_7_32_2 e_1_2_7_21_2 e_1_2_7_33_2 e_1_2_7_20_2 e_1_2_7_34_2 e_1_2_7_35_2 e_1_2_7_36_2 e_1_2_7_37_2 e_1_2_7_38_2 McMillan FD (e_1_2_7_25_2) 1986; 188 Bickel WK (e_1_2_7_26_2) 1988; 244 Ekblom M (e_1_2_7_13_2) 1993; 266 Gabrielsson J (e_1_2_7_2_2) 2006 Shapiro SS (e_1_2_7_16_2) 1968; 63 Oates HF (e_1_2_7_29_2) 1978; 206 10843903 - Am J Physiol Heart Circ Physiol. 2000 Jun;278(6):H2039-49 17571070 - Clin Pharmacol Ther. 2007 Jul;82(1):17-20 6154839 - J Cardiovasc Pharmacol. 1980;2 Suppl 1:S73-89 12426263 - Chest. 2002 Nov;122(5):1627-32 10215174 - Comput Methods Programs Biomed. 1999 Apr;59(1):19-29 8385426 - Anesthesiology. 1993 Apr;78(4):757-76 2689043 - Clin Pharmacol Ther. 1989 Dec;46(6):605-15 7574054 - Anesthesiology. 1995 Oct;83(4):747-56 17870413 - Epilepsy Res. 2007 Oct;77(1):70-4 3528096 - J Am Vet Med Assoc. 1986 Jun 15;188(12):1426-31 10411576 - J Pharmacol Exp Ther. 1999 Aug;290(2):664-71 9152377 - J Pharmacol Exp Ther. 1997 May;281(2):713-20 3336000 - J Pharmacol Exp Ther. 1988 Jan;244(1):231-6 28415 - J Pharmacol Exp Ther. 1978 Aug;206(2):268-73 2578932 - Electroencephalogr Clin Neurophysiol. 1985 Mar;60(3):228-36 3335995 - J Pharmacol Exp Ther. 1988 Jan;244(1):126-32 12780163 - Chaos. 1995 Mar;5(1):110-117 11893868 - Neuropsychobiology. 2002;45(2):106-12 8263765 - J Pharmacol Exp Ther. 1993 Dec;267(3):1061-7 8331561 - J Pharmacol Exp Ther. 1993 Jul;266(1):244-52 2898970 - Comput Appl Biosci. 1987 Nov;3(4):345-9 15255777 - Annu Rev Biomed Eng. 2004;6:453-95 12002177 - IEEE Trans Biomed Eng. 2002 May;49(5):455-62 8572353 - Anesthesiology. 1996 Jan;84(1):38-51 12606904 - Anesthesiology. 2003 Mar;98(3):621-7 16645442 - Anesthesiology. 2006 May;104(5):921-32 17689227 - Eur J Pharm Sci. 2007 Oct;32(2):85-104 17324247 - Br J Clin Pharmacol. 2007 Jul;64(1):3-13 |
| References_xml | – volume: 244 start-page: 231 year: 1988 end-page: 6 article-title: Pharmacodynamic model of tolerance: application to nicotine publication-title: J Pharmacol Exp Ther – volume: 267 start-page: 1061 year: 1993 end-page: 7 article-title: Quantification of effect delay and acute tolerance development to morphine in the rat publication-title: J Pharmacol Exp Ther – volume: 83 start-page: 747 year: 1995 end-page: 56 article-title: Validation of the alfentanil canonical univariate parameter as a measure of opioid effect on the electroencephalogram publication-title: Anesthesiology – volume: 2 start-page: S73 issue: 1 year: 1980 end-page: 89 article-title: Discontinuation syndrome following cessation of treatment with clonidine and other antihypertensive agents publication-title: J Cardiovasc Pharmacol – volume: 50 start-page: 346 year: 1983 end-page: 9 article-title: Characterization of strange attractors publication-title: Phys Rev Lett – volume: 266 start-page: 244 year: 1993 end-page: 52 article-title: Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats publication-title: J Pharmacol Exp Ther – volume: 122 start-page: 1627 year: 2002 end-page: 32 article-title: Prediction of emergency department visits for respiratory symptoms using an artificial neural network publication-title: Chest – volume: 82 start-page: 17 year: 2007 end-page: 20 article-title: Diagnosing model diagnostics publication-title: Clin Pharmacol Ther – volume: 898 start-page: 366 year: 1981 end-page: 81 article-title: Detecting strange attractors in the turbulence publication-title: Springer Lecture Notes Mathemat – volume: 104 start-page: 921 year: 2006 end-page: 32 article-title: Electroencephalographic approximate entropy changes in healthy volunteers during remifentanil infusion publication-title: Anesthesiology – volume: 98 start-page: 621 year: 2003 end-page: 7 article-title: Correlation of approximate entropy, bispectral index, and spectral edge frequency 95 (SEF95) with clinical signs of ‘anesthetic depth’ during coadministration of propofol and remifentanil publication-title: Anesthesiology – volume: 64 start-page: 3 year: 2007 end-page: 13 article-title: Population pharmacokinetic and pharmacodynamic models of remifentanil in healthy volunteers using artificial neural network analysis publication-title: Br J Clin Pharmacol – volume: 3 start-page: 345 year: 1987 end-page: 9 article-title: Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm publication-title: Comput Appl Biosci – volume: 244 start-page: 126 year: 1988 end-page: 32 article-title: Acute physical dependence in man: effects of naloxone after brief morphine exposure publication-title: J Pharmacol Exp Ther – volume: 6 start-page: 453 year: 2004 end-page: 95 article-title: Advances in quantitative electroencephalogram analysis methods publication-title: Annu Rev Biomed Eng – volume: 58 start-page: 95 year: 1992 end-page: 126 article-title: Singular‐spectrum analysis: a toolkit for short, noisy chaotic signals publication-title: Physica D – volume: 60 start-page: 228 year: 1985 end-page: 36 article-title: Electroencephalographic spectral power and lateralized motor activities publication-title: Electroencephalogr Clin Neurophysiol – start-page: 540 year: 2007 – year: 1994 – volume: 2 start-page: 365 year: 2005 end-page: 415 article-title: Constraints of artificial neural networks for rainfall‐runoff modelling: trade‐offs in hydrological state representation and model evaluation publication-title: Hydrolo Earth Syst Sci Discuss – volume: 63 start-page: 1343 year: 1968 end-page: 72 article-title: A comparative study of various tests for normality publication-title: J Am Stat Assoc – volume: 5 start-page: 110 year: 1995 end-page: 7 article-title: Approximate entropy (ApEn) as a complexity measure publication-title: Chaos – volume: 59 start-page: 19 year: 1999 end-page: 29 article-title: A procedure for generating bootstrap samples for the validation of nonlinear mixed‐effects population models publication-title: Comput Methods Programs Biomed – volume: 290 start-page: 664 year: 1999 end-page: 71 article-title: Mechanism‐based modeling of rebound tachycardia after chronic l‐propranolol infusion in spontaneous hypertensive rats publication-title: J Pharmacol Exp Ther – volume: 84 start-page: 38 year: 1996 end-page: 51 article-title: Measuring the performance of anesthetic depth indicators publication-title: Anesthesiology – year: 2006 – volume: 78 start-page: 757 year: 1993 end-page: 76 article-title: The role of the GABA receptor/chloride channel complex in anesthesia publication-title: Anesthesiology – volume: 188 start-page: 1426 year: 1986 end-page: 31 article-title: Rebound hyperglycemia following overdosing of insulin in cats with diabetes mellitus publication-title: J Am Vet Med Assoc – volume: 206 start-page: 268 year: 1978 end-page: 73 article-title: Withdrawal of clonidine: effects of varying dosage or duration of treatment on subsequent blood pressure and heart rate responses publication-title: J Pharmacol Exp Ther – volume: 77 start-page: 70 year: 2007 end-page: 4 article-title: Predictability analysis of absence seizures with permutation entropy publication-title: Epilepsy Res – start-page: 48 year: 1992 – volume: 46 start-page: 605 year: 1989 end-page: 15 article-title: Clinical pharmacology and the choice between theory and empiricism publication-title: Clin Pharmacol Ther – volume: 281 start-page: 713 year: 1997 end-page: 20 article-title: Pharmacodynamics and tolerance development during multiple intravenous bolus morphine administration in rats publication-title: J Pharmacol Exp Ther – volume: 278 start-page: H2039 year: 2000 end-page: 49 article-title: Physiological time‐series analysis using approximate entropy and sample entropy publication-title: Am J Physiol Heart Circ Physiol – volume: 45 start-page: 106 year: 2002 end-page: 12 article-title: Changes in brain complexity during valproate treatment in patients with partial epilepsy publication-title: Neuropsychobiology – volume: 32 start-page: 85 year: 2007 end-page: 104 article-title: A nonlinear feedback model capturing different patterns of tolerance and rebound publication-title: Eur J Pharm Sci – volume: 49 start-page: 455 year: 2002 end-page: 62 article-title: A computer‐aided detection of EEG seizures in infants: a singular‐spectrum approach and performance comparison publication-title: IEEE Trans Biomed Eng – ident: e_1_2_7_10_2 doi: 10.1159/000048685 – ident: e_1_2_7_22_2 doi: 10.1093/bioinformatics/3.4.345 – ident: e_1_2_7_21_2 doi: 10.1097/00000542-199601000-00005 – ident: e_1_2_7_9_2 doi: 10.1063/1.166092 – start-page: 540 volume-title: Pharmacometrics – The Science of Quantitative Pharmacology year: 2007 ident: e_1_2_7_15_2 doi: 10.1002/0470087978 – ident: e_1_2_7_32_2 doi: 10.1378/chest.122.5.1627 – volume: 244 start-page: 231 year: 1988 ident: e_1_2_7_12_2 article-title: Pharmacodynamic model of tolerance: application to nicotine publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(25)24269-0 – ident: e_1_2_7_28_2 doi: 10.1016/j.ejps.2007.06.001 – ident: e_1_2_7_6_2 doi: 10.1097/00000542-200303000-00008 – ident: e_1_2_7_33_2 doi: 10.1007/978-3-0348-8501-0 – ident: e_1_2_7_3_2 doi: 10.1097/00000542-200605000-00006 – volume: 281 start-page: 713 year: 1997 ident: e_1_2_7_14_2 article-title: Pharmacodynamics and tolerance development during multiple intravenous bolus morphine administration in rats publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)36639-X – start-page: 48 volume-title: NONMEM User's Guides Part V Introductory Guide year: 1992 ident: e_1_2_7_17_2 – volume: 267 start-page: 1061 year: 1993 ident: e_1_2_7_7_2 article-title: Quantification of effect delay and acute tolerance development to morphine in the rat publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(25)39480-2 – ident: e_1_2_7_30_2 doi: 10.1097/00000542-199304000-00020 – ident: e_1_2_7_20_2 doi: 10.1038/sj.clpt.6100241 – ident: e_1_2_7_23_2 doi: 10.1038/clpt.1989.195 – ident: e_1_2_7_8_2 doi: 10.1016/j.eplepsyres.2007.08.002 – volume: 244 start-page: 126 year: 1988 ident: e_1_2_7_26_2 article-title: Acute physical dependence in man: effects of naloxone after brief morphine exposure publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(25)24264-1 – volume: 290 start-page: 664 year: 1999 ident: e_1_2_7_27_2 article-title: Mechanism‐based modeling of rebound tachycardia after chronic l‐propranolol infusion in spontaneous hypertensive rats publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(24)34948-1 – ident: e_1_2_7_36_2 doi: 10.1016/0167-2789(92)90103-T – volume-title: Pharmacokinetic/Pharmacodynamic Data Analysis: Concepts and Applications year: 2006 ident: e_1_2_7_2_2 – volume: 188 start-page: 1426 year: 1986 ident: e_1_2_7_25_2 article-title: Rebound hyperglycemia following overdosing of insulin in cats with diabetes mellitus publication-title: J Am Vet Med Assoc doi: 10.2460/javma.1986.188.12.1426 – volume: 266 start-page: 244 year: 1993 ident: e_1_2_7_13_2 article-title: Modeling of tolerance development and rebound effect during different intravenous administrations of morphine to rats publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(25)38315-1 – volume: 206 start-page: 268 year: 1978 ident: e_1_2_7_29_2 article-title: Withdrawal of clonidine: effects of varying dosage or duration of treatment on subsequent blood pressure and heart rate responses publication-title: J Pharmacol Exp Ther doi: 10.1016/S0022-3565(25)31325-X – ident: e_1_2_7_11_2 doi: 10.1016/0013-4694(85)90036-7 – ident: e_1_2_7_38_2 doi: 10.1103/PhysRevLett.50.346 – ident: e_1_2_7_34_2 doi: 10.1146/annurev.bioeng.5.040202.121601 – ident: e_1_2_7_37_2 doi: 10.1007/BFb0091924 – ident: e_1_2_7_19_2 doi: 10.5194/hessd-2-365-2005 – volume: 63 start-page: 1343 year: 1968 ident: e_1_2_7_16_2 article-title: A comparative study of various tests for normality publication-title: J Am Stat Assoc doi: 10.1080/01621459.1968.10480932 – ident: e_1_2_7_4_2 doi: 10.1111/j.1365-2125.2007.02845.x – ident: e_1_2_7_18_2 doi: 10.1016/S0169-2607(98)00098-4 – ident: e_1_2_7_24_2 doi: 10.1097/00005344-198000021-00008 – ident: e_1_2_7_31_2 doi: 10.1152/ajpheart.2000.278.6.H2039 – ident: e_1_2_7_5_2 doi: 10.1097/00000542-199510000-00014 – ident: e_1_2_7_35_2 doi: 10.1109/10.995684 – reference: 2578932 - Electroencephalogr Clin Neurophysiol. 1985 Mar;60(3):228-36 – reference: 17870413 - Epilepsy Res. 2007 Oct;77(1):70-4 – reference: 15255777 - Annu Rev Biomed Eng. 2004;6:453-95 – reference: 10215174 - Comput Methods Programs Biomed. 1999 Apr;59(1):19-29 – reference: 3528096 - J Am Vet Med Assoc. 1986 Jun 15;188(12):1426-31 – reference: 12780163 - Chaos. 1995 Mar;5(1):110-117 – reference: 3336000 - J Pharmacol Exp Ther. 1988 Jan;244(1):231-6 – reference: 8263765 - J Pharmacol Exp Ther. 1993 Dec;267(3):1061-7 – reference: 17324247 - Br J Clin Pharmacol. 2007 Jul;64(1):3-13 – reference: 16645442 - Anesthesiology. 2006 May;104(5):921-32 – reference: 8572353 - Anesthesiology. 1996 Jan;84(1):38-51 – reference: 3335995 - J Pharmacol Exp Ther. 1988 Jan;244(1):126-32 – reference: 17689227 - Eur J Pharm Sci. 2007 Oct;32(2):85-104 – reference: 8385426 - Anesthesiology. 1993 Apr;78(4):757-76 – reference: 2689043 - Clin Pharmacol Ther. 1989 Dec;46(6):605-15 – reference: 12606904 - Anesthesiology. 2003 Mar;98(3):621-7 – reference: 10411576 - J Pharmacol Exp Ther. 1999 Aug;290(2):664-71 – reference: 17571070 - Clin Pharmacol Ther. 2007 Jul;82(1):17-20 – reference: 11893868 - Neuropsychobiology. 2002;45(2):106-12 – reference: 12002177 - IEEE Trans Biomed Eng. 2002 May;49(5):455-62 – reference: 28415 - J Pharmacol Exp Ther. 1978 Aug;206(2):268-73 – reference: 12426263 - Chest. 2002 Nov;122(5):1627-32 – reference: 7574054 - Anesthesiology. 1995 Oct;83(4):747-56 – reference: 6154839 - J Cardiovasc Pharmacol. 1980;2 Suppl 1:S73-89 – reference: 8331561 - J Pharmacol Exp Ther. 1993 Jul;266(1):244-52 – reference: 2898970 - Comput Appl Biosci. 1987 Nov;3(4):345-9 – reference: 9152377 - J Pharmacol Exp Ther. 1997 May;281(2):713-20 – reference: 10843903 - Am J Physiol Heart Circ Physiol. 2000 Jun;278(6):H2039-49 |
| SSID | ssj0013165 |
| Score | 2.0220127 |
| Snippet | WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• Remifentanil, an intravenous ultra short‐acting opioid, depresses central nervous system activity with an increase... WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Remifentanil, an intravenous ultra short‐acting opioid, depresses central nervous system activity with an increase... • Remifentanil, an intravenous ultra short-acting opioid, depresses central nervous system activity with an increase in the delta band power, and causes beta... times Remifentanil, an intravenous ultra short-acting opioid, depresses central nervous system activity with an increase in the delta band power, and causes... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 871 |
| SubjectTerms | Adult Algorithms Analgesics, Opioid - pharmacokinetics Anesthetics, Intravenous - pharmacokinetics Biological and medical sciences Blood Blood levels Central nervous system Central Nervous System - drug effects combined effect and tolerance model Data processing Depression Drug Tolerance EEG Electroencephalography - drug effects Entropy Feedback feedback model Female Humans Intravenous administration Male Medical sciences Models, Biological Models, Statistical Opioids Pharmacodynamics Pharmacology. Drug treatments Piperidines - pharmacokinetics remifentanil sigmoid Emax model temporal linear mode complexity Young Adult |
| Title | Temporal linear mode complexity as a surrogate measure of the effect of remifentanil on the central nervous system in healthy volunteers |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2125.2011.03904.x https://www.ncbi.nlm.nih.gov/pubmed/21223358 https://www.proquest.com/docview/1028080630 https://www.proquest.com/docview/866533401 https://pubmed.ncbi.nlm.nih.gov/PMC3099374 |
| Volume | 71 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1da9swFBWjT4Oxz25zt5U7KH2qgx19OHncykoZbISRQt-MZEssNLGLnUCzX7CfvXslJ6m3DsrYm4MsO5Kurs6Rr85l7Gg0ljxzWsRJwctYlNrFxiQilqVG8jxCQpDSeecvX9X5hfh8KS-7-Cc6CxP0IbYbbjQzvL-mCa5N25_kPkILV-hOiRPpuxgQnqQCwkffhrsPCqnPKkkIGbmXTPtBPXc-qLdSPbrWLXaaC9ku7oKjf0ZV3ka7frk6e8KuNg0NUSpXg9XSDIofv2lA_p-eeMoed6gWPgQzfMYe2Oo5O54EWez1CUx3p7zaEziGyU4we_2C_ZwGfaw50H_RDVB6HvDB7vYGWQLoFjS0q6apadMPFmFfE2oHCF8hhKTQr8YuZo6C4avZHOrKl3b9BBU6xXrVQpCuhlkF4QjoGshBo3khDt5nF2efpqfncZchIi4kVyIWI6fLzGaiHCayKFPH0V8hoB07JYxMTMq1RAipHMXKItVVZlgo5BPCydIgMOQv2V5VV_Y1A2Ezax2COeuQ8ypppMvwedoqxGyJ4BHLNtaQF518OmXxmOe3aBQOQ07DkNMw5H4Y8puIpdua10FC5B51DnsGt604JACdqnHE3m8sMEeHQF95dGWxG3NCjEgDFE8iBn-5h0QOOUdqHbFXwWh3L0gRMHI5wvb2zHl7A-mR90uq2XevS84TArsiYspb670bm388ndDVwb9WfMMehq1-2hx7y_aWzcq-Q6y4NIfeC_wCd3BcVw |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fb9MwELbQeAAJMX6TAeOQ0J6WKql_pH2EianANlWok_YWOYmtVXTJlLTSyl_An82dnbYLDGlCvLVKnNb2-fx9l_N3jL0fDCVPrBZhlPMiFIW2YZZFIpSFRvI8QEIQ03nn4xM1OhVfzuRZWw6IzsJ4fYh1wI1WhvPXtMApIN1d5S5FC7foVooT-bvoIaC8SwW-Hb_61t-8UohdXUnCyMi-ZNxN67nxSZ296sGlbnDYrK93cRMg_TOv8jredRvW4Tabrbrq81S-9xbzrJf_-E0F8j-NxSP2sAW28MFb4mN2x5RP2N7YK2Mv92GyOejV7MMejDea2cun7OfES2TNgP6MroEq9IDLdzdXSBRAN6ChWdR1RXE_uPChTagsIIIFn5VC32pzMbWUD19OZ1CV7mo7UFCiX6wWDXj1apiW4E-BLoF8NFoYQuFn7PTw0-RgFLZFIsJcciVCMbC6SEwiin4k8yK2HF0WYtqhVSKTURZzLRFFKkvpssh2VdbPFVIKYWWRITbkz9lWWZXmJQNhEmMs4jljkfYqmUmb4PO0UQjbIsEDlqzMIc1bBXUq5DFLrzEpnIaUpiGlaUjdNKRXAYvXLS-9isgt2ux2LG7dsE8YOlbDgL1bmWCKPoFe9OjS4DCmBBqRCSgeBQz-cg_pHHKO7DpgL7zVbn4gRszI5QD727Hn9Q0kSd69Uk7PnTQ5jwjvioApZ6637mz68WBMn3b-teFbdm80OT5Kjz6ffH3F7vvIP8XKXrOteb0wbxA6zrNd5xJ-ARqvYHI |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1ba9swFBajgzEYu1-8S3cGo091sKOLncetXehuJYwU-iZkW2KhqR2cBJr9gv3snWM5Sb11UMbeEmw5kXR09H3HR99h7G06kDxxRoRRzotQFMaFWRaJUBYGyXOKhCCm885fj9XRifh0Kk_b_Cc6C-P1ITYBN1oZjb-mBT4rXHeRNxlauEO3SpxI30UP8eRNoaKULPzwW3_7RiFuykoSREbyJeNuVs-VT-psVXdmZo6j5ny5i6vw6J9plZfhbrNfDe-xs3VPfZrKWW-5yHr5j99EIP_PUNxnd1tYC--8HT5gN2z5kO2NvC72ah_G22Ne833Yg9FWMXv1iP0ce4GsKdB_MTVQfR5ost3tBdIEMHMwMF_WdUVRPzj3gU2oHCB-BZ-TQt9qez5xlA1fTqZQlc3VdpygRK9YLefgtathUoI_A7oC8tBoXwiEH7OT4YfxwVHYlogIc8mVCEXqTJHYRBT9SOZF7Dg6LES0A6dEJqMs5kYihlSOkmWR66qsnyskFMLJIkNkyJ-wnbIq7TMGwibWOkRz1iHpVTKTLsHnGasQtEWCByxZW4POW_10KuMx1Zd4FE6DpmnQNA26mQZ9EbB403LmNUSu0Wa3Y3Cbhn1C0LEaBOzN2gI1egR6zWNKi8OoCTIiD1A8Chj85R5SOeQcuXXAnnqj3f5AjIiRyxT72zHnzQ0kSN69Uk6-N8LkPCK0KwKmGmu9dmf1-4MRfXr-rw1fs1ujw6H-8vH48wt224f9KVD2ku0s6qV9hbhxke02DuEXxJtfKg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Temporal+linear+mode+complexity+as+a+surrogate+measure+of+the+effect+of+remifentanil+on+the+central+nervous+system+in+healthy+volunteers&rft.jtitle=British+journal+of+clinical+pharmacology&rft.au=Choi%2C+Byung%E2%80%90Moon&rft.au=Shin%2C+Da%E2%80%90Huin&rft.au=Noh%2C+Moon%E2%80%90Ho&rft.au=Kim%2C+Young%E2%80%90Hac&rft.date=2011-06-01&rft.issn=0306-5251&rft.eissn=1365-2125&rft.volume=71&rft.issue=6&rft.spage=871&rft.epage=885&rft_id=info:doi/10.1111%2Fj.1365-2125.2011.03904.x&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_j_1365_2125_2011_03904_x |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon |